- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.05. | GSK sets up Nucala and Dupixent showdown in COPD | ||
| 01.05. | US is planning $500m project on 'universal vaccines;' WSJ | ||
| 01.05. | Skin Analytics' dermatology AI backed for NHS use | ||
| 01.05. | J&J's 'Swiss army knife' drug gets first FDA approval | ||
| 30.04. | Senior Republican hits out at Trump's research funding cuts | ||
| 30.04. | Novartis grabs kidney drug developer Regulus in $1.7bn deal | ||
| 30.04. | GSK "well positioned" to weather pharma tariffs | ||
| 30.04. | AZ backs up threat of manufacturing shift from Europe | ||
| 30.04. | Abeona prices rare cell disorder gene therapy at $3.1m | ||
| 30.04. | Novo Nordisk unleashes Wegovy telehealth blitz | ||
| 29.04. | Organised medicines trafficking, 12 arrests made in MHRA crackdown | ||
| 29.04. | Old bill on D2C ad tax breaks meets a new political climate | ||
| 29.04. | AACR 2025: Quintet of investigational oncological drugs puts Ascentage on positive ascent | ||
| 29.04. | AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology | ||
| 28.04. | Does the Novavax delay augur a COVID vaccine policy change? | ||
| 28.04. | France probes side effects with Valneva's chikungunya jab | ||
| 28.04. | Italfarmaco closes on EU okay for Duchenne drug | ||
| 28.04. | AbbVie makes its tariffs-driven investment play | ||
| 28.04. | Merck agrees $3.9 billion takeover of SpringWorks | ||
| 28.04. | NEJM responds to claims of bias from Justice Department | ||
| 25.04. | Ozempic patient blinded by NAION sues Novo Nordisk | ||
| 25.04. | Akeso PD-1 inhibitor cleared as Keytruda challenger advances | ||
| 25.04. | AbbVie files fast-acting Botox successor in US | ||
| 25.04. | Granite Bio makes $100m debut, and other bio financings | ||
| 25.04. | MSD has gauged its financial hit from Trump tariffs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .